scholarly journals Diagnostic Significance of Serum Fatty Acid Synthase in Patients with Pancreatic Cancer

2021 ◽  
Vol 13 (2) ◽  
pp. 115-120
Author(s):  
Hamid Reza Fazli ◽  
Maliheh Moradzadeh ◽  
Zahra Mehrbakhsh ◽  
Maryam Sharafkhah ◽  
Sahar Masoudi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Fatty Acid ◽  
Fatty Acid Synthase ◽  
Human Cancer ◽  
Elevated Serum ◽  
Diagnostic Value ◽  
Healthy Controls ◽  
Diagnostic Significance ◽  
Serum Fatty Acid ◽  
Increased Risk

BACKGROUND Pancreatic cancer is considered as the most deadly tumor among gastrointestinal cancers because of its poor prognosis. The frequently deregulated pathway in the cancer cell is associated with an increased expression of various genes, including the synthesis of fatty acids. We aimed to evaluate the level of serum fatty acid synthase (FASN) as a diagnostic marker for early diagnosis of pancreatic cancer. METHODS Serum FASN levels were measured by ELISA in 92 patients with pancreatic adenocarcinomas and in 92 healthy controls. Logistic regression analysis was used to identify independent predictors of certain diagnostic categories. RESULTS Serum FASN levels were significantly higher in patients with pancreatic cancer than in healthy controls (1.35 [0.98-2.3] ng/mL vs 1.04 [0.19-1.34] ng/mL, p < 0.001) and in smokers compared to non-smokers (1.41 [0.79-2.52] ng/mL vs 1.07 [0.21-1.74] ng/mL, p < 0.001). FASN levels and smoking were associated with increased risk of PC (1.54 [1.1- 2.14] ng/mL, p = 0.011 and 5.69 [2.68-12.09] ng/mL, p < 0.001, respectively). CONCLUSION Elevated serum FASN levels in patients with pancreatic cancer indicate the need for the production of large numbers of lipids for the survival and proliferation of human cancer cells and the diagnostic value of FASN as a new diagnostic biomarker.

scholarly journals Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shirli Tay ◽  
Gayan S. De Silva ◽  
Connor M. Engel ◽  
Nikolai Harroun ◽  
Amanda S. Penrose ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Synthase ◽  
Elevated Serum ◽  
Cross Sectional Study ◽  
Serum Samples ◽  
Serum Fatty Acid ◽  
Cross Sectional ◽  
Vascular Intervention ◽  
Artery Disease

AbstractThere are currently no serum-based evaluations that can corroborate the severity of peripheral artery disease (PAD). In this cross-sectional study, we assessed the prevalence of elevated serum fatty acid synthase (cFAS) in patients with chronic limb-threatening ischemia (CLTI) and evaluated the accuracy of its use in detecting this condition. Preoperative fasting serum samples from 87 patients undergoing vascular intervention were collected between October 2014 and September 2016. Median age was 62 years, with 56 (64%) men, and 32 (37%) with CLTI. We found that elevated cFAS content (OR 1.17; 95% CI 1.04–1.31), type 2 diabetes (T2D; OR 5.22; 95% CI 1.77–15.4), and smoking (OR 3.53; 95% CI 1.19–10.5) were independently associated with CLTI and could detect the presence of CLTI with 83% accuracy (95% CI 0.74–0.92). Furthermore, serum FAS content was positively correlated with FAS content in femoral artery plaque in patients with severe PAD ($${R}^{2}$$ R 2 = 0.22; P =  0.023). Finally, significantly higher co-localization of FAS and ApoB were observed within lower extremity arterial media (P < .001). Our findings indicate that serum FAS content is a marker for disease severity in patients with PAD, independent of concomitant T2D and smoking, and may play a key role in FAS and ApoB peripheral plaque progression.

Abstract 166: Elevated levels of serum fatty acid synthase (FAS) in patients with gastric carcinoma.

2013 ◽  
Author(s):  
Tomoaki Ito ◽  
Koichi Sato ◽  
Hiroshi Maekawa ◽  
Takashi Tada ◽  
Mutsumi Sakurada ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Gastric Carcinoma ◽  
Fatty Acid Synthase ◽  
Serum Fatty Acid

scholarly journals 3420 Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival

2019 ◽  
Vol 3 (s1) ◽  
pp. 104-105
Author(s):  
DeAnna Baker Frost ◽  
Bethany Wolf ◽  
Christine Peoples ◽  
Jessica Fike ◽  
Katherine Silver ◽  
...  
Keyword(s):  
Cox Regression ◽  
Elevated Serum ◽  
High Serum ◽  
Organ Involvement ◽  
Healthy Controls ◽  
University Of Pittsburgh ◽  
Risk Of Death ◽  
Heart Involvement ◽  
Increased Risk ◽  
Impact On Survival

OBJECTIVES/SPECIFIC AIMS: Our objective was to examine serum E2 levels in dcSSc males in relation to disease characteristics (i.e autoanitbody profile and internal organ involvement) and its impact on survival. METHODS/STUDY POPULATION: We measured serum E2 levels in 83 dcSSc men >50 years old from the University of Pittsburgh Scleroderma Center and healthy controls of similar age. Using statistical modeling, we examined the associations between circulating E2 levels, internal organ involvement, autoantibody profiles, and survival. RESULTS/ANTICIPATED RESULTS: Male dcSSc patients had significantly higher serum E2 levels compared to healthy male controls and compared to dcSSc post-menopausal women of similar age. Male dcSSc patients with high serum E2 levels had significantly more heart involvement and worse survival. Using Cox regression modeling for risk of death, increasing serum E2 levels in anti-Scl-70 antibody positive dcSSc males were associated an increased risk of death. DISCUSSION/SIGNIFICANCE OF IMPACT: DcSSc male patients have higher levels of E2 compared to healthy controls and dcSSc postmenopausal women. Elevated serum E2 levels in dcSSc males >50 are associated with heart involvement and, if anti-Scl-70 antibody positive, worse survival. Our current study expands on our previous work, not only that that E2 exerts pro-fibrotic effects on skin, but also internal organ involvement, overall survival. These data suggest an important role of estrogen imbalance in SSc.

scholarly journals Significant association between Cystatin C, Gensini score, and Potential biomarker for Increased Risk of coronary artery lesions

2020 ◽  
Author(s):  
jianyuan pan ◽  
Zhenfei Chen ◽  
Gaoliang Zhou ◽  
Jun Feng ◽  
Jing Zhang
Keyword(s):  
Coronary Artery ◽  
Cystatin C ◽  
Elevated Serum ◽  
Healthy Controls ◽  
Gensini Score ◽  
Coronary Artery Lesions ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Potential Biomarker ◽  
Increased Risk

Abstract Objective: Cystatin C (Cys C) has been proposed as a useful biomarker of early impaired kidney function and predictor of mortality risk. The present analysis is to investigate the association of serum Cystatin C with the severity of coronary artery lesions, Gensini score (GS) and the risk of CAD.Methods: 682 CAD patients (230 females, 452 males; mean age 62.6±10.7 years, range from 31 to 86 years) and 135 healthy controls (41 females, 94 males; mean age 58.0±10.3 years, range from 38 to 84 years) were recruited in the current study. ELISA was applied to measure serum Cystatin C levels. Estimated glomerular filtration rate (eGFR) and Gensini score were calculated. Results: Serum TC, LDL-C, UA, Cystatin C and HCY were significantly elevated in CAD patients compared to healthy controls. There were significant differences regarding to Cystatin C, eGFR and Gensini score among different type of CAD patients, of which AMI group had an elevated serum Cystatin C, LDL-C, HCY and Gensini score than the other two groups. When stratified by the quartiles of Cystatin C, we found that age, proportion of male patients and hypertension and diabetes, HCY and Gensini score were increased in Quartile fourth groups than in other quartile groups. Spearman's correlation test revealed positive relationship between Cystatin C, HCY and Gensini score. Multivariate logistic regression analysis revealed that serum Cystatin C level, presence of hypertension and diabetes, HCY, age and male were the risk factors for coronary artery lesions.Conclusions: In summary, our results suggested that Cystatin C is a promising clinical biomarker that provides complementary information to the established risk determinants. The serum Cystatin C level is strongly associated with Gensini score and could be used to evaluate the severity of coronary artery lesions.

scholarly journals ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Hang Yin ◽  
Lei Wang ◽  
Hai-Lin Liu
Keyword(s):  
Pancreatic Cancer ◽  
Lymph Node ◽  
Poor Prognosis ◽  
Diagnostic Marker ◽  
Clinical Stage ◽  
Healthy Controls ◽  
Diagnostic Significance ◽  
Node Metastasis ◽  
Homogeneous Assay ◽  
Electrochemiluminescence Immunoassay

We investigated in this study the expression of ENO1 in tissues and plasma of PDAC patients to evaluate its clinicopathological and diagnostic significance. ENO1 protein expression was detected in tissue microarray of human PDAC and adjacent noncancer tissues. Electrochemiluminescence immunoassay and amplified luminescent proximity homogeneous assay (AlphaLISA) were performed to measure CA19-9 and ENO1 concentration in plasma from PDAC patients and healthy controls. We demonstrated that ENO1 overexpression is positively correlated with clinical stage, lymph node metastasis, and poor prognosis of PDAC; ENO1 may function as a hopeful candidate diagnostic marker in combination with CA19-9 in PDAC diagnosis.

scholarly journals Increased Expression of the Leptin Gene in Adipose Tissue of Patients with Chronic Kidney Disease–The Possible Role of an Abnormal Serum Fatty Acid Profile

Metabolites ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 98
Author(s):  
Justyna Korczyńska ◽  
Aleksandra Czumaj ◽  
Michał Chmielewski ◽  
Maciej Śledziński ◽  
Adriana Mika ◽  
...  
Keyword(s):  
Gene Expression ◽  
Chronic Kidney Disease ◽  
Adipose Tissue ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Elevated Serum ◽  
Serum Levels ◽  
Mrna Levels ◽  
Serum Fatty Acid ◽  
Serum Leptin

Chronic kidney disease (CKD) is associated with an increased level of leptin and an abnormal fatty acid (FA) profile in the serum. However, there are no data on the associations between them, and the reason for increased serum levels in patients with CKD is not well elucidated. Recently, we found that a CKD-related abnormal FA profile caused significant changes in the expression of genes involved in lipid metabolism in hepatocytes. The aim of this study was to examine whether leptin gene expression in subcutaneous adipose tissue (SAT) of patients with CKD may contribute to increased serum levels of this adipokine and whether the abnormal serum FA profile observed in CKD patients has an impact on leptin gene expression in adipocytes. The FA profile was measured in serum samples from patients with CKD and controls by GC–MS. The relative mRNA levels of leptin were measured in SAT by Real-Time PCR. Moreover, the effect of the CKD-related abnormal FA profile on leptin gene expression was studied in in vitro cultured 3T3-L1 adipocytes. Patients with CKD had higher concentrations of serum leptin than controls and higher expression level of the leptin gene in SAT. They also had increased serum monounsaturated FAs and decreased polyunsaturated FAs. The incubation of adipocytes with FAs isolated from CKD patients resulted in an increase of the levels of leptin mRNA. Increased leptin gene expression in SAT may contribute to elevated concentrations of these adipokine in patients with CKD. CKD-related alterations of the FA profile may contribute to elevated serum leptin concentrations in patients with CKD by increasing the gene expression of this adipokine in SAT.

Sign in / Sign up

Export Citation Format

Share Document